Mitomycin C does not inhibit exacerbation of granular corneal dystrophy type II induced by refractive surface ablation

Byoung Jin Ha, Tae Im Kim, Seung Il Choi, R. Doyle Stulting, Dong Ho Lee, Hyun Soo Cho, Eung Kweon Kim

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: To evaluate the effect of mitomycin C (MMC) on the exacerbation of corneal opacity that occurs in patients with granular corneal dystrophy type II (GCD II) after refractive corneal surface ablation. Methods: Ten eyes of patients with GCD II who underwent refractive corneal surface ablation with MMC were compared with 10 eyes that were not treated with MMC. Best spectacle-corrected visual acuity, the degree of corneal opacity, and contrast sensitivity were evaluated at least 3 years after surgery. Corneal opacities were quantified using Pentacam densitometry maps. Results: No measured between-group value showed a statistically significant difference. Conclusion: Simultaneous application of MMC does not prevent exacerbation of GCD II after refractive corneal surface ablation.

Original languageEnglish
Pages (from-to)490-496
Number of pages7
JournalCornea
Volume29
Issue number5
DOIs
Publication statusPublished - 2010 May 1

Fingerprint

Mitomycin
Corneal Opacity
Contrast Sensitivity
Densitometry
Visual Acuity
Corneal dystrophy Avellino type

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

@article{f7b313d9ed1c4591800bc1d76fb45dba,
title = "Mitomycin C does not inhibit exacerbation of granular corneal dystrophy type II induced by refractive surface ablation",
abstract = "Purpose: To evaluate the effect of mitomycin C (MMC) on the exacerbation of corneal opacity that occurs in patients with granular corneal dystrophy type II (GCD II) after refractive corneal surface ablation. Methods: Ten eyes of patients with GCD II who underwent refractive corneal surface ablation with MMC were compared with 10 eyes that were not treated with MMC. Best spectacle-corrected visual acuity, the degree of corneal opacity, and contrast sensitivity were evaluated at least 3 years after surgery. Corneal opacities were quantified using Pentacam densitometry maps. Results: No measured between-group value showed a statistically significant difference. Conclusion: Simultaneous application of MMC does not prevent exacerbation of GCD II after refractive corneal surface ablation.",
author = "Ha, {Byoung Jin} and Kim, {Tae Im} and Choi, {Seung Il} and Stulting, {R. Doyle} and Lee, {Dong Ho} and Cho, {Hyun Soo} and Kim, {Eung Kweon}",
year = "2010",
month = "5",
day = "1",
doi = "10.1097/ICO.0b013e3181c3258a",
language = "English",
volume = "29",
pages = "490--496",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Mitomycin C does not inhibit exacerbation of granular corneal dystrophy type II induced by refractive surface ablation. / Ha, Byoung Jin; Kim, Tae Im; Choi, Seung Il; Stulting, R. Doyle; Lee, Dong Ho; Cho, Hyun Soo; Kim, Eung Kweon.

In: Cornea, Vol. 29, No. 5, 01.05.2010, p. 490-496.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mitomycin C does not inhibit exacerbation of granular corneal dystrophy type II induced by refractive surface ablation

AU - Ha, Byoung Jin

AU - Kim, Tae Im

AU - Choi, Seung Il

AU - Stulting, R. Doyle

AU - Lee, Dong Ho

AU - Cho, Hyun Soo

AU - Kim, Eung Kweon

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Purpose: To evaluate the effect of mitomycin C (MMC) on the exacerbation of corneal opacity that occurs in patients with granular corneal dystrophy type II (GCD II) after refractive corneal surface ablation. Methods: Ten eyes of patients with GCD II who underwent refractive corneal surface ablation with MMC were compared with 10 eyes that were not treated with MMC. Best spectacle-corrected visual acuity, the degree of corneal opacity, and contrast sensitivity were evaluated at least 3 years after surgery. Corneal opacities were quantified using Pentacam densitometry maps. Results: No measured between-group value showed a statistically significant difference. Conclusion: Simultaneous application of MMC does not prevent exacerbation of GCD II after refractive corneal surface ablation.

AB - Purpose: To evaluate the effect of mitomycin C (MMC) on the exacerbation of corneal opacity that occurs in patients with granular corneal dystrophy type II (GCD II) after refractive corneal surface ablation. Methods: Ten eyes of patients with GCD II who underwent refractive corneal surface ablation with MMC were compared with 10 eyes that were not treated with MMC. Best spectacle-corrected visual acuity, the degree of corneal opacity, and contrast sensitivity were evaluated at least 3 years after surgery. Corneal opacities were quantified using Pentacam densitometry maps. Results: No measured between-group value showed a statistically significant difference. Conclusion: Simultaneous application of MMC does not prevent exacerbation of GCD II after refractive corneal surface ablation.

UR - http://www.scopus.com/inward/record.url?scp=77951765347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951765347&partnerID=8YFLogxK

U2 - 10.1097/ICO.0b013e3181c3258a

DO - 10.1097/ICO.0b013e3181c3258a

M3 - Article

C2 - 20299970

AN - SCOPUS:77951765347

VL - 29

SP - 490

EP - 496

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 5

ER -